The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Treatment of Hepatitis C Virus-Related Cirrhosis: A Randomized, Controlled Trial of Interferon Alfa–2B Versus No Treatment
Open accessAbstract
To examine the effects of interferon (IFN) therapy on clinical, biochemical, and histological features in patients with compensated hepatitis C virus (HCV)–related cirrhosis, we have conducted a randomized, controlled trial of IFN therapy versus observation. Eight centers included a total of 99 patients with biopsy–proven cirrhosis. IFN–α2b, 3 million units three times per week, or no antiviral therapy was given for 48 weeks. Twenty–three patients dropped out. End–of–treatment biochemical response was not observed in any of the 39 controls but was observed in 6 of the 47 treated patients (P < .02); sustained biochemical response was obtained in only 2 treated patients. Controls and treated patients did not significantly differ with regard to the changes in serum level of albumin, bilirubin, α–fetoprotein, in plasma prothrombin, in histological activity, or liver collagen content. During trial or follow–up (160 ± 57 weeks), hepatocellular carcinoma developed in 9 controls and 5 treated patients (NS); decompensation of cirrhosis occurred in 5 controls and 7 treated patients. Seven controls and 10 treated patients died. In conclusion, in patients with compensated HCV–related cirrhosis, a 48–week course of IFN therapy is safe and is able to induce end–of–treatment biochemical response in a significant proportion of patients. However, a 48–week course of IFN therapy usually fails to achieve sustained response and, within the limit of this study, did not significantly improve the 3–year outcome. Therefore, a longer course of IFN therapy or combination therapy with ribavirin should be evaluated in patients with HCV–related cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Self-citationHepatitis C: the clinical spectrum of disease.
Hoofnagle, J. H. (1997) · Hepatology · doi:10.1002/hep.510260703 · Cited by 765
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Once cirrhosis is established, there is no conclusive evidence that anti-viral therapy can prevent or delay the occurrence of HCC [41,42].”
BackgroundClinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
Heathcote, E. J., Shiffman, M. L., Cooksley, W. G. E., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432302 · Cited by 874
Metadata
- Authors
- Valla, D.-C., Chevallier, M., Marcellin, P., Payen, J.-L., Trepo, C., Fonck, M., Bourliere, M., Boucher, E., Miguet, J.-P., Parlier, D., Lemonnier, C., & Opolon, P.
- Venue
- Hepatology
- Published
- 1999-06
- Volume
- 29
- Issue
- 6
- Pages
- 1870-1875
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2096121062
- Cited by
- 211
- References
- 2
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Hepatitis C Virus-Related Cirrhosis: A Randomized, Controlled Trial of Interferon Alfa–2B Versus No Treatment. https://app.cochat.ai/papers/10.1002/hep.510290616
- The paper
- Valla, D.-C., Chevallier, M., Marcellin, P., Payen, J.-L., Trepo, C., Fonck, M., Bourliere, M., Boucher, E., Miguet, J.-P., Parlier, D., Lemonnier, C., & Opolon, P. (1999). Treatment of Hepatitis C Virus-Related Cirrhosis: A Randomized, Controlled Trial of Interferon Alfa–2B Versus No Treatment. Hepatology. https://doi.org/10.1002/hep.510290616
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.